Fintel reports that on April 14, 2023,
HC Wainwright & Co.
maintained
coverage of Arcadia Biosciences (NASDAQ:RKDA) with
a Buy recommendation.
Analyst Price Forecast Suggests 970.46% Upside
As of April 6, 2023,
the average one-year price target for Arcadia Biosciences is $71.40.
The forecasts range from a low of $20.20 to a high of $126.00.
The average price target represents an increase of 970.46% from its latest reported closing price of $6.67.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arcadia Biosciences
is $12MM, an increase of 20.89%.
The projected annual non-GAAP EPS
is -$0.65.
What are Other Shareholders Doing?
VitalStone Financial
holds 0K shares
representing 0.00% ownership of the company.
Geode Capital Management
holds 177K shares
representing 20.70% ownership of the company.
In it’s prior filing, the firm reported owning 178K shares, representing
a decrease
of 0.29%.
The firm
decreased
its portfolio allocation in RKDA by 52.25% over the last quarter.
State Street
holds 102K shares
representing 11.87% ownership of the company.
No change in the last quarter.
Harbour Investments
holds 0K shares
representing 0.00% ownership of the company.
No change in the last quarter.
FNCMX – Fidelity Nasdaq Composite Index Fund
holds 4K shares
representing 0.43% ownership of the company.
No change in the last quarter.
What is the Fund Sentiment?
There are 38 funds or institutions reporting positions in Arcadia Biosciences.
This is an increase
of
3
owner(s) or 8.57% in the last quarter.
Average portfolio weight of all funds dedicated to RKDA is 0.00%,
a decrease
of 50.36%.
Total shares owned by institutions decreased
in the last three months by 27.89% to 2,370K shares.
The put/call ratio of RKDA is 0.00, indicating a
bullish
outlook.
Arcadia Biosciences Background Information
(This description is provided by the company.)
Arcadia Biosciences is a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients. The company’s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company’s GoodHemp™ seed catalog delivers genetically superior hemp seeds, transplants and extracts, applying the company’s proprietary crop innovation technology, ArcaTech™, to an emerging crop.
See all Arcadia Biosciences regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
